Histone deacetylase inhibitor romidepsin induces efficient tumor cell lysis via selective down-regulation of LMP1 and c-myc expression in EBV-positive diffuse large B-cell lymphoma

Highlights • Novel treatment strategy for overcoming poor prognosis of EBV-positive DLBCL is needed. • The histone deacetylase inhibitor romidepsin shows selective cytotoxicity in EBV-positive DLBCL. • Romidepsin inhibits the expression of LMP1 and c-myc in EBV-positive cells. • Dual inhibition of L...

Full description

Saved in:
Bibliographic Details
Published in:Cancer letters 2015-08, Vol.364 (2), p.89-97
Main Authors: Shin, Dong-Yeop, Kim, Areumnuri, Kang, Hye Jin, Park, Sunhoo, Kim, Dong Wan, Lee, Seung-Sook
Format: Article
Language:English
Subjects:
Animals
Antibiotics, Antineoplastic - pharmacology
Apoptosis
c-myc
Cancer
Cancer therapies
Cell Line, Tumor
Clinical trials
Cytotoxicity
Depsipeptides - pharmacology
Diffuse large B-cell lymphoma
Down-Regulation - drug effects
Epstein-Barr virus
Epstein-Barr Virus Infections - pathology
Epstein-Barr Virus Infections - virology
Female
Hematology, Oncology and Palliative Medicine
Herpesvirus 4, Human - drug effects
Herpesvirus 4, Human - genetics
Herpesvirus 4, Human - metabolism
Histone Deacetylase Inhibitors - pharmacology
Humans
Latent membrane protein-1
Lymphoma
Lymphoma, Large B-Cell, Diffuse - drug therapy
Lymphoma, Large B-Cell, Diffuse - virology
Medical research
Mice
Mice, Inbred NOD
Mice, SCID
Polymerase chain reaction
Proteins
Proto-Oncogene Proteins c-myc - biosynthesis
Proto-Oncogene Proteins c-myc - genetics
Random Allocation
Romidepsin
Studies
Viral Matrix Proteins - biosynthesis
Viral Matrix Proteins - genetics
Xenograft Model Antitumor Assays
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • Novel treatment strategy for overcoming poor prognosis of EBV-positive DLBCL is needed. • The histone deacetylase inhibitor romidepsin shows selective cytotoxicity in EBV-positive DLBCL. • Romidepsin inhibits the expression of LMP1 and c-myc in EBV-positive cells. • Dual inhibition of LMP1 and c-myc activates EBV lytic cycle in EBV-positive cells. • Romidepsin could be a promising agent for treating EBV-positive DLBCL.
ISSN:0304-3835
1872-7980
DOI:10.1016/j.canlet.2015.03.016